A Highly Specific and Discriminatory FISH Assay for Distinguishing Between Benign and Malignant Melanocytic Neoplasms

被引:149
|
作者
Gerami, Pedram [1 ,2 ]
Li, Gu [3 ]
Pouryazdanparast, Pedram [1 ]
Blondin, Beth [3 ]
Beilfuss, Beth [1 ]
Slenk, Carl [3 ]
Du, Jing [3 ]
Guitart, Joan [1 ,2 ]
Jewell, Susan [3 ]
Pestova, Katerina [3 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA
[3] Abbott Mol Labs, Des Plaines, IL USA
关键词
fluorescence in situ hybridization; melanoma; second-generation FISH probes; 9p21; 8q24; IN-SITU HYBRIDIZATION; ATYPICAL SPITZ NEVI/TUMORS; CUTANEOUS MELANOMA; CHROMOSOME; 9P21; NEVI; DIAGNOSIS; TUMORS; EXPRESSION; GAINS; 11Q13;
D O I
10.1097/PAS.0b013e31824b1efd
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The diagnosis of certain melanocytic proliferations remains one of the most challenging areas in pathology. In recent times, fluorescence in situ hybridization (FISH) has emerged as a promising diagnostic aid to conventional microscopy. We previously showed that a 4-probe FISH assay targeting 6p25 (RREB1), 6q23 (MYB), Cep6 (centromere 6), and 11q13 (CCND1) could discriminate between histologically unequivocal melanomas and benign nevi with a sensitivity of 86.7% and specificity of 95.4%. However, the sensitivity of the assay is approximately 70% in melanomas with spitzoid morphology. Furthermore, differentiating true gains from tetraploidy may cause difficulties in interpretation by inexperienced examiners. Here we refine the current probe set to better target spitzoid melanomas and more easily distinguish cells with imbalanced copy number aberrations from tetraploid cells. Using FISH data from 3 training sets of 322 tumors, including 152 melanomas and 170 nevi, we identified 9p21, 6p25, 11q13, and 8q24 as a probe set with improved discriminatory power in differentiating melanomas from nevi. In a validation set of 51 melanomas and 51 nevi this probe set had a sensitivity of 94% and specificity of 98%, compared with the original probe set that had a sensitivity of 75% and specificity of 96% in the same validation cohort. We propose that by incorporating 9p21 into the 4-probe FISH assay, with a new diagnostic algorithm, this new probe set would have improved discriminatory power in melanocytic neoplasms and improved sensitivity for detecting spitzoid melanomas, as demonstrated by our previous studies.
引用
收藏
页码:808 / 817
页数:10
相关论文
共 50 条
  • [1] Distinguishing between Benign and Malignant Melanocytic Nevi by In Vivo Multiphoton Microscopy
    Balu, Mihaela
    Kelly, Kristen M.
    Zachary, Christopher B.
    Harris, Ronald M.
    Krasieva, Tatiana B.
    Koenig, Karsten
    Durkin, Anthony J.
    Tromberg, Bruce J.
    CANCER RESEARCH, 2014, 74 (10) : 2688 - 2697
  • [2] Epidermal consumption in benign and malignant melanocytic neoplasms
    Bandino, Justin P.
    Kazlouskaya, Viktoryia
    Ergin, Seniz
    Moles-Poveda, Paula
    Cleaver, Nathan J.
    Kabigting, Filamer D.
    Shackelton, Jeffrey B.
    Thieu, Khanh
    Elston, Dirk M.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2015, 42 (12) : 937 - 943
  • [3] DISTINGUISHING BENIGN AND MALIGNANT MELANOCYTIC LESIONS WITH THE AGNOR METHOD
    FRIEDMAN, RJ
    GRIN, CM
    HEILMAN, E
    WEISER, J
    GOTTLIEB, GJ
    WALDO, E
    RIGEL, DS
    KOPF, AW
    DERMATOLOGIC CLINICS, 1991, 9 (04) : 689 - 693
  • [4] BENIGN AND MALIGNANT MELANOCYTIC NEOPLASMS OF DOMESTIC-ANIMALS
    GOLDSCHMIDT, MH
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1985, 7 : 203 - 212
  • [5] Genomic Copy Number Profiling of Benign and Malignant Cutaneous Melanocytic Neoplasms
    Geiersbach, Katherine
    Guo, Ruifeng
    Sukov, William
    Flotte, Thomas
    Erickson, Lori
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 296 - 297
  • [6] The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms
    Pinczewski, Joel
    Slominski, Andrzej
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 860 - 864
  • [7] Genomic Copy Number Profiling of Benign and Malignant Cutaneous Melanocytic Neoplasms
    Geiersbach, Katherine
    Guo, Ruifeng
    Sukov, William
    Flotte, Thomas
    Erickson, Lori
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 296 - 297
  • [8] Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid neoplasms
    Nagar, Sapna
    Ahmed, Samreen
    Peeples, Claire
    Urban, Nichole
    Boura, Judy
    Thibodeau, Bryan
    Akervall, Jan
    Wilson, George
    Long, Graham
    Czako, Peter
    AMERICAN JOURNAL OF SURGERY, 2014, 207 (04): : 596 - 601
  • [9] Distribution of transforming growth factor-1β in benign and malignant melanocytic neoplasms
    Golomb, C
    Badiavas, E
    Butmarc, J
    Wikel, C
    Falanga, V
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 485 - 485
  • [10] Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions
    Keijser, S
    Missotten, GS
    Bonfrer, JM
    de Wolff- Rouendaal, D
    Jager, MJ
    de Keizer, RJW
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (02) : 213 - 217